Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity
Related Experiment Video
Updated: Dec 8, 2025
Gabriele Manzella1, Leonie D Schreck1, Willemijn B Breunis1,2
1University Children's Hospital, Department of Oncology and Children's Research Center, Steinwiesstrasse 75, CH-8032, Zurich, Switzerland.
Abstract:
Cancer therapy is currently shifting from broadly used cytotoxic drugs to patient-specific precision therapies. Druggable driver oncogenes, identified by molecular analyses, are present in only a subset of patients. Functional profiling of primary tumor cells could circumvent these limitations, but suitable platforms are unavailable for most cancer entities. Here, we describe an in vitro drug profiling platform for rhabdomyosarcoma (RMS), using a living biobank composed of twenty RMS patient-derived xenografts (PDX) for high-throughput drug testing. Optimized in vitro conditions preserve phenotypic and molecular characteristics of primary PDX cells and are compatible with propagation of cells directly isolated from patient tumors. Besides a heterogeneous spectrum of responses of largely patient-specific vulnerabilities, profiling with a large drug library reveals a strong sensitivity towards AKT inhibitors in a subgroup of RMS. Overall, our study highlights the feasibility of in vitro drug profiling of primary RMS for patient-specific treatment selection in a co-clinical setting.
Insights
This study introduces a new in vitro drug profiling platform for rhabdomyosarcoma (RMS) using patient-derived xenografts. The platform enables personalized treatment selection by identifying patient-specific drug sensitivities, particularly to AKT inhibitors.
Area of Science:
- Oncology
- Translational Medicine
- Drug Discovery
Background:
- Cancer therapy is transitioning towards personalized medicine, but identifying targeted therapies remains challenging.
- Druggable oncogenes are found in a limited number of cancer patients.
- Functional profiling of primary tumor cells offers an alternative but lacks suitable platforms for many cancers.
Purpose of the Study:
- To develop and validate an in vitro drug profiling platform for rhabdomyosarcoma (RMS).
- To enable high-throughput drug testing using a living biobank of RMS patient-derived xenografts (PDX).
- To facilitate patient-specific treatment selection in a co-clinical setting.
Main Methods:
- Established a living biobank of twenty RMS patient-derived xenografts (PDX).
- Optimized in vitro conditions to maintain phenotypic and molecular characteristics of PDX cells.
- Performed high-throughput drug screening using a large drug library on primary RMS cells.
Main Results:
- The developed platform successfully preserved key characteristics of primary RMS cells.
- Drug profiling revealed heterogeneous, patient-specific drug responses.
- A significant subgroup of RMS demonstrated strong sensitivity to AKT inhibitors.
Conclusions:
- The study demonstrates the feasibility of an in vitro drug profiling platform for RMS.
- This platform supports patient-specific treatment selection by identifying individual drug vulnerabilities.
- The findings highlight the potential of AKT inhibitors for a subset of RMS patients.
More Related Videos
09:21Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
